A friend of mine in Shanghai got a lunchtime skin booster injection, picked up bubble tea on the way back, and was on a client call by 2pm. Nobody blinked. That is where aesthetic medicine sits in China in 2026: somewhere between a spa visit and a dentist appointment. I run a marketing agency here, and this is one of the fastest, most confusing, most opportunity-rich sectors I work in right now.
I’m Olivier Verot, founder of Gentlemen Marketing Agency in Shanghai since 2012. My team runs China market entry and digital campaigns for injectable brands, device makers, and clinic groups, so what follows comes from actual launches, not a desk review of industry reports.
China’s Aesthetic Medicine Market in 2026
The medical aesthetics industry in China has grown from a niche for the wealthy into a mainstream consumer category. According to iiMedia Research (艾媒资讯), the medical aesthetics services market is on track to reach close to RMB 295 billion in 2026, up from roughly RMB 276 billion in 2025, a growth rate few consumer categories in China can match right now. What used to require a special trip to a private clinic in Beijing or Shanghai now happens in second and third tier cities too, in shopping mall clinics, dermatology chains, and dental groups that added an aesthetics menu.
Foreign brands notice the growth numbers first. What they miss is how different the buying behavior is here compared to the US or Europe. Chinese consumers do not walk into a clinic cold. They research for weeks, sometimes months, on social platforms before booking anything.
Growth is not coming only from Tier 1 cities anymore. Chengdu, Hangzhou, Wuhan, and a long list of Tier 2 and Tier 3 cities now have real clinic density, and local consumers there are just as informed as anyone in Shanghai. Mall based clinic chains, sometimes with ten or twenty locations across a province, are pushing the category into places it never reached before. If your China strategy assumes the buyer only lives in one or two megacities, you are already behind.
From luxury to routine
Five years ago, a facial injection was a splurge. Now it is closer to a haircut: planned, budgeted, repeated every few months. That shift changed who buys, how often, and what they expect to pay. Price sensitivity is real, and so is brand loyalty once a consumer finds a doctor or clinic they trust.
Payment habits shifted too. Installment tools built into apps like Alipay’s Huabei make a mid tier treatment feel like a manageable monthly cost rather than a lump sum. Clinics that offer flexible payment, clear package pricing, and no hidden fees convert noticeably better than clinics that make a client ask for a quote by phone. If your pricing page still says “contact us for pricing,” you are asking a Chinese consumer to do extra work she is not willing to do.
What Is Actually Selling: Injectables, Skin, and Devices
Three categories dominate the conversation, and each behaves differently in marketing terms.
Injectables and light medical aesthetics
Botulinum toxin and dermal fillers remain the anchor products, but the bigger story is what people call qing yi mei, or “light medical aesthetics”: lower cost, lower downtime treatments like skin boosters, mesotherapy, and thread treatments. These are positioned as maintenance, not transformation. Marketing that promises dramatic change tends to underperform here. Marketing that promises a fresher, less tired look does better.
Domestic Chinese injectable brands have also gotten much stronger. A decade ago, “imported” was almost automatically a selling point. Now local competitors have closed the gap on quality and price, and some consumers actively prefer them. A foreign injectable brand cannot just say “made in Korea” or “made in France” and expect that to close the sale on its own. You need a real story: how the product performs, how it is used, why a doctor picked it over a domestic alternative.
Devices and energy-based treatments
Radiofrequency, ultrasound, and laser devices have a strong following, partly because they photograph and video well. A treatment that looks satisfying on camera, think visible tightening or a glowing after shot, spreads fast on short video platforms. Device makers selling into China should think about this from day one: does the treatment itself generate shareable content, or does it need help?
Regulation moved on this category recently, and it matters if you sell devices. Under a 2024 NMPA notice, radiofrequency skin treatment devices, the exact category most home and clinic tightening devices fall into, needed a Class III medical device registration to be legally manufactured, imported, or sold in China, with enforcement delayed to April 1, 2026 to give the industry time to comply, as Xinhua reported when the delay was announced. That date has now passed. If your RF device does not carry a current Class III registration, it cannot legally be sold or used in a Chinese clinic today, regardless of what certification it holds elsewhere.
The device side of this market is also more competitive than most foreign manufacturers expect. Domestic device makers move fast, price aggressively, and market directly to clinics through trade shows and distributor networks. A foreign device brand usually wins on clinical credibility and training quality, not on price. Lead with the data, the certifications, and the after sales training program, because that is what a serious clinic buyer is actually comparing.
Skin health as the gateway
A large share of new clients enter the category through skin treatments rather than injectables. Acne scarring, pigmentation, and pore concerns are common starting points. Brands that build trust here, before ever mentioning a needle, tend to convert better later. Skin is the low commitment first date. Injectables are the second date.
This matters for content planning too. A skincare or dermatology brand that only talks about advanced procedures skips over the audience that is still deciding whether to trust the category at all. Educational content about skin barrier health, sun protection, and realistic timelines does quiet, steady work that a flashy before and after post cannot do on its own.
Who Is Buying: A Younger, Faster Consumer
The average age of a first time aesthetic medicine consumer in China has dropped steadily. Women in their mid twenties are now a core segment, not an outlier. Many start with skin treatments in university or shortly after starting work, well before the wrinkle concerns that drive the category in Western markets.
This younger buyer researches differently than her mother would have. She compares doctors like she compares hotels: reviews, before and after photos, credentials, and price transparency all matter. She also churns clinics faster if trust breaks down even once.
Men are showing up too
Male consumers are a real and growing segment now, mostly for skin treatments, hairlines, and jaw contouring. It is still a smaller share of the market, but the growth rate is worth watching if your brand has products that suit a male audience without needing a completely separate positioning.
Small, repeated purchases beat one big one
A typical new client is not planning one big procedure. She is planning a routine: a skin treatment every month or two, a light injectable a few times a year, maybe a device based treatment before a big event or holiday. This pattern rewards clinics and brands that build ongoing relationships, membership style pricing, and reminders, over anyone selling a single expensive transaction and hoping the client returns on her own.
Where They Research and Book
This is the part foreign brands get wrong most often. You cannot run a Google or Instagram playbook here. The platforms are different, and so is the buying journey.
Xiaohongshu
Xiaohongshu is where most research starts. Users search a treatment name the way they would search a restaurant, and they expect real reviews, honest before and after posts, and doctor credentials, not polished ad copy. Fake or exaggerated claims get called out fast in the comments, and that damage sticks.
Douyin
Douyin drives awareness and, increasingly, direct bookings through livestreaming and in app clinic pages. Short video content that shows the treatment process, the clinic environment, and the doctor’s manner tends to outperform pure result focused content. People want to see who is holding the needle. If you are building a paid and organic Douyin plan from scratch, I go deeper on the tactics in this Douyin advertising guide for foreign brands.
So-Young and vertical apps
So-Young, known locally as Xinyang, is a dedicated aesthetic medicine platform: part review site, part booking engine, part community. It is smaller in raw traffic than Xiaohongshu or Douyin, but the intent is high. Users on So-Young are usually close to booking, comparing specific clinics and specific doctors by name. For a foreign clinic group or device brand, a strong presence here is worth more per visitor than almost anywhere else.
WeChat still closes the loop. Official accounts, mini programs for booking, and private consultations through customer service accounts handle the parts of the journey that need a real conversation: pricing questions, medical history, and scheduling.
AI search: the diligence layer nobody is watching yet
There is a newer step in this research journey, and it does not show up in most platform breakdowns because it is not consumer facing. Distributors, clinic procurement staff, and even journalists now open DeepSeek or Doubao and ask a direct question before they ever get on a call with a sales rep: is this brand legitimate, and who else already uses it. If your product pages, press mentions, and doctor case studies on Xiaohongshu are not written so an AI model can extract and quote a clear answer, that buyer forms an opinion from whatever fragments the model finds, and it is not necessarily flattering. Put the plain facts, who makes it, where it is registered, which clinics already use it, in ordinary text on your own site and on the case studies you publish, not buried inside a PDF brochure or a slide deck nobody outside a sales meeting ever opens.
Trust, Safety, and Why Consumers Are Cautious
Chinese media has covered enough botched procedures and unlicensed clinics that consumers now do real diligence before booking. Doctor credentials, hospital or clinic licensing, and product origin (imported versus domestic, genuine versus grey market) are checked, discussed, and debated in comment sections constantly. Grey market and counterfeit product is a live risk in this category specifically, and if your brand is exposed to it, our guide to protecting your brand in China walks through the legal and practical options.
This caution is not a marketing obstacle to work around. It is the actual buying criteria. A brand or clinic that leans into transparency, showing licenses, showing the real doctor, showing where a device or injectable comes from, earns trust faster than one that leans into glossy imagery alone.
I have seen clinics spend a fortune on polished campaign visuals while skipping the basics: a clear photo of the doctor’s license on their Xiaohongshu profile, a simple explanation of what the product actually is, honest notes about recovery time and possible side effects. Those basics do more for booking rates than another round of studio photography.
Regulation and what it means for marketing
China regulates medical aesthetics advertising closely. Claims about specific outcomes, comparisons to competitors, and certain types of before and after content face restrictions depending on the platform and the product category. Devices and injectables also need the correct registration before they can legally be marketed or used in a clinical setting, and as the RF device example above shows, those requirements do change with real deadlines attached.
None of this is medical or legal advice, and every brand should work with qualified local counsel and a licensed clinical partner before launch. What I can say from the marketing side: build your content plan around what you can prove and what you are allowed to say, not around what performs best in another market. A campaign built on unverifiable claims does not survive contact with Chinese platform moderation or with a skeptical comment section. For the fuller rundown on advertising limits and what changed most recently, I cover it in more depth in How to Grow a Cosmetic Surgery Business in China.
How Foreign Brands, Device Makers, and Clinics Should Approach This Market
I get three types of clients in this category: aesthetics brands looking to sell products through distributors or cross border channels, device manufacturers looking for clinical partners, and clinic groups looking to open or expand locally. Each needs a different starting point.
Brands and device makers
If you are selling a product rather than a service, your first job is education, not selling. Chinese doctors and clinic owners want clinical data, training support, and a partner who understands local registration requirements. Your content should speak to two audiences at once: the professional buyer deciding whether to stock your product, and the end consumer who will eventually ask for it by name because they saw it discussed online.
Distributor selection matters more here than in most industries. A distributor with the right clinic relationships can get your product into a hundred clinics in a year. The wrong one will sit on your inventory and let a competitor take the market instead. Vet distributors on their existing clinic network, not just on the size of their sales pitch.
Take Radovan, who runs a small radiofrequency device workshop outside Belgrade. His device had a loyal following among dermatologists in the Balkans and Germany, and he assumed the same clinical study and the same English language deck that opened doors in Europe would work in China. It did not. Eleven months of emailing distributors produced two replies and no orders.
What changed was not the product. His team had the clinical study translated into Chinese, built a short training video with a Chinese speaking trainer running the device on camera instead of a slide deck of before and after photos, and partnered with one distributor who already had real relationships in a mid tier city cluster rather than chasing a national deal. Two local doctors then posted their own case results on Xiaohongshu under their own names, not the brand’s account, because a review from a named doctor carries more weight with buyers than anything a manufacturer posts about itself. Within eight months the device was running in eleven clinics across two provinces, entirely through that one distributor’s network. Radovan did not need a bigger budget. He needed the registration in order, the proof, the training, and a local voice doing the talking.
Clinic groups
If you are opening a physical location, your reputation gets built or broken on Xiaohongshu and So-Young before your first client walks in the door. Get real reviews flowing early, get your doctors visible and named, and treat your booking flow on WeChat and So-Young as part of the product, not an afterthought.
Foreign owned clinic groups also do well when they stop trying to look like a Western clinic dropped into China and instead build a brand that feels native to the platforms it lives on. That means short video content, real staff faces, and a tone that is warm and a little conversational, not clinical and stiff. This article looks at the market mostly from the brand and device side. If you are the one running the clinic itself, licensing, advertising limits, platform by platform tactics, I wrote the longer operator specific playbook in How to Grow a Cosmetic Surgery Business in China.
Content and compliance together
The brands that do well here treat content strategy and regulatory compliance as one function, not two separate teams that argue at the end. That means involving legal and clinical partners in the content calendar from the start, not after the copy is written.
This is a market where the upside is real, the growth is not slowing down, and the mistakes are avoidable if you plan for the local buying journey instead of importing one from somewhere else. If you want help figuring out where your brand fits in this category, take a look at our services page and we can talk through what makes sense for your specific product or clinic model.
FAQ
Do I need a Chinese distributor to sell an aesthetic device or injectable, or can I sell directly to clinics?
In practice, almost every foreign device or injectable brand works through at least one local distributor, because clinics buy from suppliers who already handle registration paperwork, after sales training, and Mandarin language support. Selling direct is possible on paper, but it removes the relationships that get a new product onto a clinic’s treatment menu in the first place. Choose the distributor on their existing clinic network, not the size of their pitch.
Is the registration process the same for a device, an injectable, and a clinic license?
No. A device or an injectable needs its own product registration before it can be marketed or used clinically, separate from the license a clinic needs to operate. A brand can have a fully registered product sitting unused if the clinics buying it are not themselves properly licensed, and vice versa. Confirm both tracks before you commit marketing budget to a launch.
Which platform matters more for a brand or device maker: Xiaohongshu, So-Young, or WeChat?
They serve different jobs. Xiaohongshu builds the awareness and credibility that gets a treatment or product searched by name. So-Young reaches the buyer already close to booking, or for a brand, the clinic decision maker researching suppliers. WeChat closes the loop once a relationship exists. A brand selling to clinics rather than consumers usually gets more return from So-Young and direct outreach than from a large Xiaohongshu content budget alone.
How long before a new device or injectable brand sees real traction in Chinese clinics?
Plan for six to twelve months before volume becomes meaningful, even with a strong distributor. The first months go into registration confirmation, distributor training, and building the first doctor case studies other clinics will trust. Brands that expect meaningful revenue inside a quarter usually cut corners on training or documentation, and that shows up later as returns or complaints.
Should a foreign brand worry about domestic Chinese competitors on price?
Yes, and pretending otherwise wastes marketing budget. Domestic injectable and device makers have closed much of the quality gap and can price below most imported products. Competing on price alone is a losing strategy for a foreign brand. Compete on clinical data, training quality, and after sales support, the things a domestic competitor usually has not built out yet.
Gentlemen Marketing Agency is a China-focused digital marketing agency based in Shanghai, and this is one of the categories we work in most: launch strategy for injectable and device brands, distributor vetting, Xiaohongshu and So-Young content, and the compliance-aware campaigns this sector requires. Want to know what your brand could do in the Chinese market? Get in touch for a free consultation.
